New trial drug a 'Trojan Horse' attacking pancreatic cancer
An investigational drug that acts like a Trojan Horse to deliver cancer killing agents for pancreatic cancer is being studied at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) that treats cancer patients with promising new drugs.
The Phase 2 clinical trial tests the effectiveness and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas (PDA) who have not responded to prior standard treatment. PDA is a malignant tumor arising from the duct cells within a gland in the pancreas, and represents about 80 percent of all pancreatic cancers.
Pancreatic cancer is extremely difficult to treat and the fourth most common cause of cancer-related deaths in the U.S., with more than 43,000 new cases reported in 2010 and 37,000 deaths attributed to this disease each year. Tumors may grow in the pancreas without any early symptoms, which means that the disease is often in an advanced stage when it is diagnosed.
"The drug's effectiveness works like a Trojan Horse because it is prepared in albumin which pancreatic cancer likes to eat, thereby transporting the drug into the cancer cells and destroying them," said Jasgit Sachdev, M.D., of the Virginia G. Piper Cancer Center Clinical Trials.
Preclinical results showing the drug induced complete tumor remissions in the laboratory were presented at the American Association for Cancer Research (AACR) 2012 Annual Meeting.
"We are encouraged by early study results and looking forward to the next step in evaluating the activity and safety of INNO-26 in patients with advanced pancreatic ductual adenocarcinomas," said Dr. Ramesh Ramanathan, Medical Director of Virginia G. Piper Cancer Center Clinical Trials, and Clinical Professor and Deputy Director of the Clinical Translational Research Division at TGen.
Los Angeles-based CytRx holds the worldwide rights to INNO-206, which is a tumor-targeted conjugate of the widely used chemotherapeutic agent doxorubicin. INNO-206 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with pancreatic cancer.
Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare is co-lead site Stand Up to Cancer of the Pancreatic Cancer Dream Team, comprised of scientists working collaboratively to develop new treatments for pancreatic cancer.
TGen Drug Development (TD2), a TGen subsidiary, is managing this Phase 2 clinical trial on behalf of CytRx.
The Phase 2 clinical trial will enroll up to 27 patients at multiple clinical sites in the U.S. The trial patients will be treated with intravenously administered INNO-206 once every three weeks for up to eight cycles. Trial patients will be evaluated for complete and partial tumor responses, side effects and overall survival.
Provided by The Translational Genomics Research Institute
- Results of new drug for pancreatic cancer patients published Oct 04, 2011 | not rated yet | 0
- Pancreatic cancer clinical trial results released Apr 03, 2012 | not rated yet | 0
- New investigational compound targets pancreatic cancer cells Sep 15, 2010 | not rated yet | 0
- TGen, Virginia G. Piper Cancer Center studying new breast cancer drug Jul 20, 2011 | not rated yet | 0
- 'Seena' clinical trials named for pancreatic cancer advocate Dec 01, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Cancer 22 hours ago | not rated yet | 0
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
Cancer 22 hours ago | 5 / 5 (1) | 0
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer May 24, 2013 | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer May 24, 2013 | 5 / 5 (2) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer May 24, 2013 | 5 / 5 (4) | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
4 hours ago | 5 / 5 (1) | 4
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
22 hours ago | 3.7 / 5 (3) | 3 |
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
4 hours ago | not rated yet | 1
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
20 hours ago | 3 / 5 (2) | 0 |
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
23 hours ago | 5 / 5 (5) | 0 |
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
4 hours ago | not rated yet | 0